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Imaging
AbstrAct
Background the canada-Denmark (canDen) 
definitions of spinal Mri lesions allow a detailed 
anatomy-based evaluation of inflammatory and 
structural lesions in vertebral bodies and posterior 
elements of the spine in patients with axial 
spondyloarthritis (axSpa). the objective was to examine 
the reliability, responsiveness and discrimination of 
scores for spinal inflammation, fat, bone erosion and 
new bone formation based on the canDen system and 
to describe patterns of inflammatory and structural 
lesions and their temporal development.
Methods 49 patients with axSpa from an investigator-
initiated, randomised, placebo-controlled trial of 
adalimumab underwent spinal Mri at weeks 0/6/24/48. 
Mr images were scored according to the canDen 
system and the Spondyloarthritis research consortium 
of canada (SParcc) method. total scores, and various 
subscores, were created by summing individual lesion 
scores.
Results the canDen spine inflammation score had 
high responsiveness, similar to the SParcc Mri spine 
index (guyatt’s responsiveness index 1.88 and 1.67, 
respectively), and discriminated between adalimumab 
and placebo treatment already at 6 weeks’ follow-
up (P=0.03). anterior/posterior corner inflammation 
subscores showed similar responsiveness. inter-reader 
reliability for the canDen spine inflammation and fat 
scores was good to very good for status and change 
scores (intraclass correlation coefficient (icc)=0.71–
0.92). reliability for canDen new bone formation and 
erosion scores was good to very good for status scores 
(icc=0.61–0.75) but, due to minimal progression, poor 
for change scores (icc≤0.40).
Conclusions the canDen spine inflammation score 
showed good responsiveness, discrimination between 
active treatment and placebo and reliability. the canDen 
spine structural scores had good cross-sectional reliability, 
but longer studies are needed to investigate their 
sensitivity to change.
Trial registration number nct01029847; results.
InTRoduCTIon
Axial spondyloarthritis (axSpA) is a chronic 
inflammatory disease that affects the sacro-
iliac joints and the spine.1 MRI can detect 
inflammatory lesions (bone marrow oedema 
Key messages
What is already known about this subject?
 ► Patients with axial spondyloarthritis (axSpa) have 
different trajectories of inflammatory and structural 
spinal lesions during the disease course. 
 ► Detailed scoring of Mr images of the vertebral 
bodies and posterior elements of the spine 
is possible using the 2009 canada-Denmark 
(canDen) definitions for inflammatory and 
structural spinal lesions.
What does this study add?
 ► the canDen spine inflammation score showed 
good reliability, responsiveness and discriminated 
well between active treatment and placebo, and 
it has inherent good face validity as posterior 
elements of the spine are also assessed.
How might this impact on clinical practice?
 ► the canDen scores are not intended to be used 
to diagnose axSpa, but rather to allow detailed 
monitoring in research settings of changes over 
time in patients who have already been diagnosed 
with axSpa. 
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(BME)/osteitis), and structural lesions (erosions, bone 
spurs, ankylosis and fat metaplasia). The histopatho-
logical correlation of MRI inflammation and structural 
changes are mostly unknown, but BME of the facet joints 
has been shown to correlate with inflammatory cell infil-
trates.2 
In 2009, the founders of the Canada-Denmark 
(CANDEN) MRI working group (RL, WM, MØ, SJP) 
developed definitions and an atlas of inflammatory3 and 
structural lesions4 of the spine, and reported the reli-
ability of scoring the individual lesions in a multireader 
exercise.5 6 The CANDEN approach allows a systematic 
assessment of MR images of the spine from the perspec-
tive of diagnostic ascertainment, and of quantifying 
both active inflammatory and structural abnormalities 
according to their precise anatomical locations and 
their relations over time.7 The definitions were based on 
sagittal T1-weighted and Short Tau Inversion Recover 
(STIR) MRI sequences of the vertebral bodies and the 
posterior elements of the vertebrae (ie, the costotrans-
verse, costovertebral and facet joints, transverse and 
spinous processes and the adjacent soft tissues). Since 
then, a score for spinal fat lesions (Fat Spondyloarthritis 
Spine Score (FASSS))8 and a score for new bone forma-
tion,9–11 based on the CANDEN MRI definitions has been 
developed. Reference images are available online.12
The Spondyloarthritis Research Consortium of Canada 
(SPARCC) MRI spine index is a well-established MRI 
scoring method for spinal inflammation. The standard 
SPARCC 23-discovertebral unit (DVU) and 6-DVU 
methods cover the vertebral bodies,13 but not lesions 
located in the posterior elements of the spine or the 
soft tissues adjacent to the spine. An extended SPARCC 
scoring method that captured lesions in the posterior 
elements has been developed,14 but has not been used 
in clinical trials. The SPARCC method is applied on only 
three consecutive sagittal slices of each DVU and may 
therefore not provide information on the total inflam-
matory load of the patients. In contrast, the CANDEN 
MRI definitions for inflammatory and structural lesions 
comprise detailed information on the anatomical loca-
tion of lesions in the vertebral bodies as well as in the 
posterior elements (figure 1), and may therefore provide 
more accurate information on the total inflammatory 
load and allow detailed analyses of changes in lesions at 
specific locations over time.
The aim of this study was to develop and validate an 
anatomy-based inflammation score, the CANDEN spine 
inflammation score and to further develop and validate 
CANDEN spine scores of erosion, fat and new bone 
formation. Moreover, we aimed to apply the CANDEN 
MRI definitions for spinal inflammation, fat metaplasia, 
erosion and new bone formation in an investigator-initi-
ated, randomised, double-blind, placebo-controlled trial 
of adalimumab versus placebo to describe the frequen-
cies of inflammatory and structural lesions and their 
development over time.
MeTHods
study design
Forty-nine patients participated in a randomised, double-
blind, placebo-controlled trial of adalimumab versus 
placebo (ASIM trial,  ClinicalTrials. gov NCT01029847). 
All patients fulfilled the Assessment in Spondyloarthritis 
International Society (ASAS) criteria for axSpA and had 
sacroiliitis on MRI and/or radiography. The patients were 
randomly assigned to adalimumab 40 mg subcutaneously 
every other week or placebo for 6 weeks, thereafter all 
patients were treated with adalimumab 40 mg subcutane-
ously every other week to week 48. The six patients not 
responding at week 24 had their treatment changed to 
another tumour necrosis factor (TNF) inhibitor at the 
discretion of the treating rheumatologist. Further details 
of this trial, including whole-body MRI outcomes, are 
described in a separate article.15
The study took place at five rheumatology outpatient 
clinics in The Capital and Zealand Regions of Denmark 
from February 2010 to March 2014. All imaging examina-
tions were performed at the Department of Radiology, 
Copenhagen University Hospital Herlev.
Image acquisition and scoring
MRI of the spine was performed at baseline and at weeks 
6, 24 and 48. The spine was imaged in three parts (sepa-
rately for cervical, thoracic and lumbar spine). MRI was 
performed in a single high-field Philips Medical Systems 
Achieva scanner (3.0 T) by sagittal T1-weighted turbo 
spin echo (repetition time: 518 ms, echo time: 8 ms, 
matrix (cerv./thor./lumb.): 200×143/300×213/300×213, 
field of view (FOV) (cerv./thor./lumb.): 178×150 mm/
270×150 mm/270×150 mm, slice thickness 4 mm, inters-
lice gap 0.4 mm) and STIR (repetition time: 4990–8530 
ms, echo time: 80 ms and inversion time: 120 ms, matrix 
(cerv./thor./lumb.): 272×212/272×215/272×215, FOV 
(cerv./thor./lumb.): 270×230 mm/270×150 mm/270×23
0 mm, slice thickness 4 mm, interslice gap 0.8 mm).
All MRI scans were read in chronological order by 
an experienced (SJP) and a newly trained (SK) reader 
blinded to other imaging and clinical data. Images were 
scored according to the definitions in the CANDEN 
MRI spine system3–6 and by the 23-DVU SPARCC MRI 
spine index using a web-based data entry interface 
(COPECARE SAMRI (Spondyloarthritis MRI module), 
figure 1). To ensure proper calibration of the two MRI 
readers for the SPARCC method, one of the developers 
of the SPARCC system (WM) also scored all images for 
the 23-DVU SPARCC MRI spine index.
Radiographs were obtained at baseline and at 48 weeks 
and were scored in known chronology by the modified 
Stoke Ankylosing Spondylitis Spine Score (mSASSS) by 
one experienced reader (SJP) in known chronological 
order, blinded to all other data.
scoring of inflammatory lesions
Inflammation, new bone formation and erosion scores 
were developed from the CANDEN definitions of lesions 
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and scoring,5 6 in a similar way as FASSS. The develop-
ment and validation of FASSS based on the CANDEN 
MRI definitions has previously been reported.8
The spine is divided into 23 levels from C2/C3 to L5/
S1. Central sagittal slices are the sagittal slices that include 
the spinal canal; the pedicle may be partially seen but is 
not continuous between the vertebral body and posterior 
elements3 5 (figure 1). Lateral sagittal slices are the sagittal 
slices that are located lateral to the spinal canal, and either 
the pedicle must be continuous between vertebral body 
and posterior elements or the slice is lateral to the pedicle. 
Only BME is scored, except for posterior element soft tissue 
oedema. To calculate the CANDEN spine inflammation 
score, a set of scoring rules are defined.
Vertebral bodies
In central sagittal slices, anterior and posterior corner 
inflammatory lesions are scored as 0 (absent) or 1 
(present); in DVUs in thoracic and lumbar spine (T1/T2 
and below), a score of 1 is added for large lesions (≥25% 
of the anteroposterior (AP) diameter of the vertebral 
endplate and/or height of the vertebral body, perpendic-
ular to the endplate).3 Non-corner inflammatory lesions 
(BME located between the corners of a vertebral body) are 
scored as 0 (absent), 2 (present); in DVUs in the thoracic 
and lumbar spine, a score of 2 is added for large non-corner 
lesions (≥25% of the height of the vertebral body, perpen-
dicular to the endplate). It was decided to assign the score 
2 for non-corner lesions, while 1 for corner lesions (both 
Figure 1 (A) User interface used for scoring of sagittal images according to the Canada-Denmark scoring system. Twenty-
three discovertebral units (DVUs) are assessed. Fat lesions are scored in a similar way as inflammatory lesions, except that 
the posterior elements (FIL, SP, ST and TP/R) are not assessed for fat lesions. Fat lesions follow the principles of inflammation, 
except that posterior elements are not assessed. aCIL, anterior corner inflammatory lesion; NIL, non-corner inflammatory 
lesion; pCIL, posterior corner inflammatory lesion; FIL, facet joint inflammatory lesion; SP, spinous process inflammatory lesion; 
ST, soft tissue inflammatory lesion; aLIL, anterior lateral inflammatory lesion; pLIL, posterior lateral inflammatory lesion; TP/R, 
transverse process/rib; aCOBE, anterior corner bone erosion; pCOBE posterior corner bone erosion; NOBE, non-corner bone 
erosion; aCANK, anterior corner ankylosis; pCANK, posterior corner ankylosis; NANK, non-corner ankylosis; aCOS, anterior 
corner spur; pCOS, posterior corner spur; NOS, non-corner spur; FANK, facet joint ankylosis. (B) Axial view of inflammatory 
lesions. Note that as sagittal images are used for scoring, the boundaries illustrated in axial view may vary a few millimeters 
depending on the exact placement of the sagittal slices, when following the definition of central and lateral slices.
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doubled if large, see definitions), because the area of this 
anatomical region is typically larger than the corner areas, 
and because each vertebral endplate contains two corner 
regions but only one non-corner region, thereby giving 
the same total weight to the two lesion types in the central 
sagittal slices. If a corner lesion in any central slice involves 
>50% of the AP diameter of the vertebra, it is counted as a 
combined corner and non-corner lesion.
In lateral sagittal slices in the thoracic and lumbar spine, 
BME is scored if located at the anterior or posterior corner; 
these antero-lateral and postero-lateral inflammatory 
lesions are scored as 0 (absent) or 1 (present). All lesions 
are scored based on anatomical location; for example, if a 
lesion is visible at the anterior corner on a central sagitttal 
slice and in the anterior half of the vertebral body on a 
lateral slice, it is scored as the combination of an anterior 
corner lesion (sagittal slice) and an antero-lateral corner 
lesion (lateral slice).
Posterior elements
For each of the 23 levels from C2/C3 to L5/S1: facet joint 
inflammatory lesions on left and right side, spinous process 
inflammatory lesions and soft tissue inflammatory lesions 
(hyperintense signal on STIR at ligaments and entheses at 
the posterior elements of the vertebrae) are each scored as 
0 (absent) or 1 (present). For each of the 17 vertebrae from 
T1 to L5: rib/transverse process inflammatory lesions are 
scored as 0 (absent) or 1 (present) on left and right side. 
Inflammation in the costovertebral joints was not scored 
separately but as inflammation of rib/transverse process 
and/or postero-lateral corner inflammation, when present 
at these locations.
The total scoring range for the CANDEN spine inflam-
mation score is 0–582. The range for the vertebral body 
subscore is 0–456, and the range for the posterior elements 
subscore is 0–126.
scoring of structural lesions
Fat metaplasia (FASSS) is scored as previously described,6 8 
the scoring range is 0–456. The method for scoring erosions 
is similar to the method for scoring spine inflammation, 
except that erosions are only assessed in central sagittal 
slices. Anterior and posterior corner erosions are scored 1, 
non-corner erosion is scored 2, in DVUs in the thoracic and 
lumbar spine, a score of 1 is added for large corner lesions 
and a score of 2 is added for large non-corner lesions. 
Erosions are not scored in the facet joints or other poste-
rior elements. The scoring range for the CANDEN spine 
erosion score is 0–320. To obtain the CANDEN spine new 
bone formation score, at each level, the presence of anterior 
corner ankylosis, posterior corner ankylosis and non-corner 
ankylosis are each scored as 0 (absent) or 6 (present), ante-
rior corner, posterior corner and non-corner bone spurs 
are each scored as 0 (absent) or 2 (present), facet joint 
ankylosis is scored as 0 (absent) or 1 (present), and all indi-
vidual lesion scores are summed. The new bone formation 
scores were chosen to be consistent with the scores used 
in the radiographic mSASSS system that assigns a score of 
2 for bone spur and a score of 3 for ankylosis (in total a 
score of 6 for two ankylosed corners that are opposing each 
other). Scoring range for the CANDEN spine new bone 
formation score is 0–460; the vertebral body subscore has 
a range of 0–414 and the facet joints subscore has a range 
of 0–46.
The estimated reading time including data entry for 
obtaining the CANDEN spine inflammation score was 
not recorded systematically, but judged to be in the range 
of 10–45 min for all four timepoints depending on the 
amount of inflammation, similar to the SPARCC method in 
most cases. Total scoring time for inflammation and struc-
tural lesions in the spine were in the range 15–90 min per 
patient for four timepoints.
statistical analysis
Data were characterised by descriptive statistics and corre-
lations were assessed by Spearman’s correlation analysis. 
Difference between groups in change from baseline to 
weeks 6, 24 and 48 was assessed by Mann-Whitney U tests 
with continuity correction according to the predefined 
statistical analysis plan. Analysis of covariance (ANCOVA) 
with group allocation and baseline score as covariates and 
changes in continuous outcome variables as dependent 
outcomes were performed as post hoc secondary analyses 
to take differences in baseline values into account. Stand-
ardised response mean (SRM) was calculated as the overall 
mean change score divided by the SD of the change scores, 
while Guyatt’s responsiveness index (GRI) was calculated as 
the mean change score in the adalimumab group divided 
by the SD of the change scores in the placebo group at 
week 6; values ≥0.8 were judged to represent a large degree 
of responsiveness.16 Inter-reader agreement was assessed 
using a two-way random effects single measure model of 
intraclass correlation coefficient (ICC)1 3 based on absolute 
agreement. ICCs≥0.6 were considered to represent good 
reliability, and ≥0.8 very good reliability. Smallest detectable 
change (SDC) was calculated from baseline to week 24 as 
1.96×SDdifference in change scores/(√2√k) for the k=2 readers (SJP 
and SK).
All MRI results at the patient level are reported as the 
mean score of the two primary MRI readers (SJP and SK). 
All MRI results at the lesion level are reported for the most 
experienced primary reader (SJP) for conciseness; largely 
similar results were obtained for the other reader (SK, data 
not shown). No imputation of missing data was performed, 
39 of 49 patients had complete data at week 48. All statis-
tical analyses were performed using R V.3.4.0.
ResulTs
The patients had mean age 38 years (range 20–61), 51% 
were males, 73% were HLA-B27 positive, mean symptom 
duration 12 years (range 0–45) and mean baseline Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI) 
6.4 (range 4.2–9.8). Twenty-eight patients (57%) fulfilled 
the modified New York radiographic criteria for anky-
losing spondylitis.
 o
n
 22 M
arch 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000624 on 16 M
arch 2018. Downloaded from
 
5Krabbe S, et al. RMD Open 2018;4:e000624. doi:10.1136/rmdopen-2017-000624
Imaging
The anatomical distribution of inflammatory lesions at 
baseline and changes during the study
At baseline, 40 patients (82%) had a CANDEN spine 
inflammation vertebral body subscore ≥1. Six patients 
(12%) had a CANDEN spine inflammation posterior 
elements subscore ≥1. Patients with inflammatory 
lesions in the posterior elements all had concomi-
tant inflammatory lesions in the vertebral bodies, not 
necessarily at the same level. Overall, inflammatory 
lesions were seen at 161 (14%) of 1127 levels (table 1). 
Fourteen (9%) of the involved levels had inflamma-
tory lesions of both vertebral bodies and posterior 
elements, 134 levels (83%) had inflammatory lesions 
of only the vertebral bodies and 13 levels (8%) had 
inflammatory lesions of only the posterior elements. 
Inflammatory lesions were most frequently located at 
the anterior, posterior, antero-lateral and postero-lat-
eral corners of the thoracic or lumbar spine (figure 2). 
Facet joint inflammation comprised 26 (81%) of 32 
inflammatory lesions in the posterior elements.
Table 1 The anatomical distribution of inflammatory and structural lesions in the spine
Cervical spine (%) Thoracic spine (%) Lumbar spine (%) Total spine (%)
Inflammatory lesions 
  Anterior corner 8 (16) 20 (41) 25 (51) 35 (71)
  Posterior corner 2 (4) 14 (29) 9 (18) 21 (43)
  Non-corner 2 (4) 7 (14) 5 (10) 10 (20)
  Antero-lateral corner –* 11 (22) 14 (29) 20 (41)
  Postero-lateral corner –* 16 (33) 4 (8) 19 (39)
  Transverse processes/ribs –* 2 (4) 1 (2) 2 (4)
  Facet joints 3 (6) 4 (8) 3 (6) 6 (12)
  Spinous processes 0 (0) 1 (2) 0 (0) 1 (2)
  Soft tissue 0 (0) 0 (0) 0 (0) 0 (0)
Structural lesions 
  Type
  Anterior corner 
   Fat 8 (16) 22 (45) 16 (33) 27 (55)
   Erosion 0 (0) 1 (2) 0 (0) 1 (2)
   Bone spurs 3 (6) 0 (0) 2 (4) 3 (6)
   Ankylosis 1 (2) 1 (2) 3 (6) 5 (10)
  Posterior corner 
   Fat 4 (8) 8 (16) 11 (22) 16 (33)
   Erosion 0 (0) 1 (2) 0 (0) 1 (2)
   Bone spurs 1 (2) 0 (0) 0 (0) 1 (2)
   Ankylosis 0 (0) 3 (6) 1 (2) 4 (8)
  Non-corner 
   Fat 1 (2) 2 (4) 6 (12) 7 (14)
   Erosion 1 (2) 4 (8) 2 (4) 5 (10)
   Bone spurs 0 (0) 0 (0) 0 (0) 0 (0)
   Ankylosis 0 (0) 3 (6) 1 (2) 3 (6)
  Antero-lateral corner 
   Fat –* 8 (16) 9 (18) 14 (29)
  Postero-lateral corner 
   Fat –* 6 (12) 3 (6) 6 (12)
  Facet joints 
   Ankylosis 5 (10) 4 (8) 4 (8) 6 (12)
Percentage of patients with a score ≥1 according to the Canada-Denmark spine MRI definitions by anatomical location and lesion category.
Cervical spine is defined here as C2/C3 to C7/T1 (6 discovertebral units (DVUs)), thoracic spine as T1/T2 to T12/L1 (12 DVUs) and lumbar 
spine as L1/L2 to L5/S1 (5 DVUs).
*Antero-lateral corner lesions, postero-lateral corner lesions and transverse processes/ribs were assessed only in the thoracic and lumbar 
spine.
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Corner inflammatory lesions of the vertebral bodies were 
seen in 131 (16%) of 833 thoracic or lumbar DVUs. Fifty-
three of these DVUs (40%) had lesions visible on both 
central and lateral slices, while 60 DVUs (46%) had lesions 
that were only visualised on central slices and 18 DVUs 
(14%) had lesions that were only visualised on lateral slices.
Most inflammatory lesions present at baseline had 
disappeared after 24 weeks, while new inflammatory 
lesions developed very infrequently (table 2).
CAnden spine inflammation score: discrimination
The mean CANDEN spine inflammation score was 8.8 
(SD 12) at baseline. The vertebral bodies subscore 
had a mean value of 8.2 (SD 11) and constituted the 
major part of the total score. The posterior elements 
subscore had mean value 0.6 (SD 1.7). The CANDEN 
spine inflammation score decreased significantly 
more in the adalimumab group than in the placebo 
group at week 6 (table 3, figure 3). At weeks 24 and 48, 
no significant differences between groups remained 
(see online supplementary table 1). In post hoc 
secondary analyses, similar results were found using 
ANCOVA with baseline score as covariate, except that 
the difference between groups in SPARCC MRI spine 
index (23-DVU) at week 6 was highly significant when 
using ANCOVA (P=0.008) (figure 3). SPARCC results 
by the SPARCC developer can be found in online 
supplementary table 2.
CAnden spine inflammation score: responsiveness
The CANDEN spine inflammation score demon-
strated a large degree of responsiveness at week 6 
(GRI 1.88) comparable to the responsiveness of the 
SPARCC MRI spine index (GRI 1.67). The vertebral 
body subscore had a higher responsiveness (GRI 1.99) 
than the posterior elements subscore (GRI 0.84). 
At week 6, BASDAI (GRI 1.32) was less responsive 
than the CANDEN spine inflammation score and the 
SPARCC MRI spine index (table 4). At weeks 24 and 
48, the responsiveness of the CANDEN spine inflam-
mation score was moderate (SRM 0.57 and 0.55) and 
comparable with the SPARCC MRI spine index (SRM 
0.57 and 0.55).
Figure 2 The distribution at baseline of inflammatory and 
structural lesions across vertebral bodies and posterior 
elements at each level from C2/C3 to L5/S1. Bars represent 
the number of patients with lesion by type and anatomical 
location. BME, bone marrow oedema; ERO, erosion; FAT, fat 
lesion; NBF, new bone formation (ankylosis/bone spur); PE, 
posterior elements; VB, vertebral body.
Table 2 The disappearance of inflammatory lesions of the spine between baseline and week 24 during adalimumab therapy 
and the development of new lesions by anatomical location
Lesion type
Disappearance:
number of lesions 
no longer present at 
week 24/number of 
lesions present at 
baseline (%)
Development:
number of lesions 
present at week 24 
but not at baseline/
number of baseline 
zero scores (%)
Disappearance:
number of patients 
with disappearance of 
at least one lesion at 
week 24 (%)
Development:
number of patients 
with development of 
at least one lesion at 
week 24 (%)
Anterior corner lesions 107/159 (67) 7/1657 (0.4) 23/42 (55) 3/42 (7)
Posterior corner lesions 38/54 (70) 3/1766 (0.2) 14/42 (33) 2/42 (5)
Non-corner lesions 15/27 (56) 1/1789 (0.1) 6/42 (14) 1/42 (2)
Antero-lateral corner 
lesions
41/53 (77) 3/2571 (0.1) 14/42 (33) 3/42 (7)
Postero-lateral corner 
lesions
58/69 (84) 3/2563 (0.1) 14/42 (33) 1/42 (2)
Transverse processes/
ribs
3/4 (75) 3/1312 (0.2) 2/42 (5) 2/42 (5)
Facet joints 18/26 (69) 3/1794 (0.2) 5/42 (12) 2/42 (5)
Spinous processes 1/2 (50) 0/908 (0.0) 1/42 (2) 0/42 (0)
Soft tissue 0/0 (NA) 0/910 (0.0) 0/42 (0) 0/42 (0)
NA, not available.
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CAnden spine inflammation score: construct validity
The CANDEN spine inflammation score was highly 
correlated with SPARCC MRI Spine Inflammation Index 
at baseline (rho=0.98, P<0.001), and changes in these 
two MRI measures were highly correlated (from week 
0 to 6: rho=0.90, P<0.001; from week 0 to 24: rho=0.96, 
P<0.001). The CANDEN inflammation score correlated 
weakly with C-reactive protein (CRP) (rho=0.21, P=0.14), 
with the posterior elements subscore reaching statistical 
significance (rho=0.37, P=0.008), while the vertebral body 
subscore did not (rho=0.19, P=0.20). This was similar 
in magnitude to the correlation between SPARCC MRI 
Spine Inflammation Index and CRP (rho=0.18, P=0.22).
No significant correlations were found at baseline 
between CANDEN spine inflammation score and visual 
analogue scale (VAS) pain (rho=−0.13, P=0.37), BASDAI 
(rho=−0.11, P=0.45), Bath Ankylosing Spondylitis Func-
tional Index (BASFI) (rho=−0.06, P=0.70) or Ankylosing 
Spondylitis Disease Activity Score (ASDAS) (rho=0.14, 
P=0.35). Changes in CANDEN spine inflammation score 
were not significantly correlated with changes in these 
clinical measures of disease activity and in CRP at week 6 
or week 24 (data not shown).
The anatomical distribution of fat metaplasia at baseline and 
changes during the study
The most frequent structural lesions at baseline were fat 
anterior corner lesions in the thoracic and lumbar spine 
(figure 2). At the patient level, a decrease in CANDEN 
spine inflammatory score from baseline to week 24 was 
associated with an increase in the FASSS score (rho=−0.59, 
P<0.001). The mean increase in FASSS at week 24 was 1.7 
(range −4 to 24). Change in FASSS at week 6 tended to be 
higher in the adalimumab group than the placebo group 
(table 3).
Twenty-four (3%) of 906 DVUs had an increase in fat 
score at week 24, 21 (88%) of these had a concomitant 
decrease in BME score, while 3 (13%) had no concomi-
tant decrease in BME. Eighty-three DVUs had a decrease 
in BME without a concomitant increase in fat score at 
week 24. A decrease in fat at week 24 was observed in 5 
DVUs. At the individual lesion level, 7 (3%) of 233 fat 
lesions present at baseline had disappeared at week 24, 
while 51 new fat lesions had developed, 43 (84%) of the 
new fat lesions were located in exactly the same locations 
where inflammation had been present at baseline.
structural scores: responsiveness, construct validity and 
comparison with radiography
FASSS showed large responsiveness (GRI 0.41) at week 6, 
but low responsiveness (SRM 0.28 and 0.27) at weeks 24 
and 48. Responsiveness for the CANDEN spine erosion 
score and the CANDEN spine new bone formation score 
was low during 48 weeks of follow-up, similar to mSASSS 
of radiographs (table 4). The CANDEN spine new bone 
formation score correlated with clinical examination 
(Bath Ankylosing Spondylitis Metrology Index (BASMI), 
Table 3 Construct validity as assessed by change in scores from baseline to week 6 in adalimumab group compared with 
placebo group
Adalimumab Placebo Difference in 
change score 
from baseline to 
week 6, P value
Baseline 
(n=25)
Change at 
week 6 (n=24) Baseline (n=24)
Change at 
week 6 (n=23)
CANDEN spine total inflammation score 10.2 (13) −5.7 (9.2) 7.3 (10) −0.8 (3.0) 0.03
  Vertebral body subscore 9.5 (12) −5.2 (8.3) 6.9 (9.9) −0.9 (2.6) 0.03
   Anterior corner subscore 3.9 (5.6) −2.0 (3.8) 3.3 (4.3) −0.3 (1.2) 0.21
   Posterior corner subscore 1.5 (2.6) −0.9 (1.8) 1.3 (2.4) 0.0 (0.4) 0.01
   Non-corner subscore 1.5 (3.2) −0.3 (0.8) 0.9 (2.4) −0.2 (0.8) 0.21
   Lateral corner subscore 2.5 (3.8) −1.9 (3.2) 1.5 (2.5) −0.4 (1.8) 0.03
  Posterior elements subscore 0.7 (2.3) −0.5 (1.7) 0.4 (0.8) 0.1 (0.6) 0.16
SPARCC MRI spine index (23-DVU) 11.0 (14) −6.3 (10) 8.7 (13) −1.5 (3.7) 0.05
CANDEN spine erosion score 0.7 (1.7) 0.0 (0.2) 0.6 (0.9) 0.0 (0.1) 0.58
Fat Spondyloarthritis Spine Score 7.8 (11) 0.7 (2.7) 3.2 (5.5) 0.1 (0.6) 0.35
CANDEN new bone formation score 9.3 (26) 0.2 (0.6) 5.7 (12) 0.3 (0.9) 0.92
mSASSS 8.0 (15) NA 6.3 (12) NA NA
BASDAI 6.3 (1.2) −2.4 (2.2) 6.4 (1.5) −0.6 (1.8) 0.01
All values as mean (SD). Significance tests for difference in change scores at week 6 between groups were calculated by Mann-
Whitney U tests with continuity correction. Two patients in the adalimumab group had missing BASDAI values at week 6 and were 
excluded from the BASDAI results. MRI scores were the average of the two readers. Lateral corner subscore is the sum of antero-
lateral and postero-lateral lesion scores.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CANDEN, Canada-Denmark; DVU, discovertebral unit; mSASSS, 
modified Stoke Ankylosing Spondylitis Spine Score; NA, not available; PE, posterior elements; SPARCC, Spondyloarthritis Research 
Consortium of Canada.
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rho=0.41, P=0.003) as well as with radiographic scores 
(mSASSS, rho=0.49, P<0.001). No significant correlations 
of the CANDEN spine erosion score were found.
MRI demonstrated new bone formation in nine (18%) 
patients at baseline (from C2/C3 to L5/S1). Ankylosis 
was found in eight (16%) patients; five patients had anky-
losis of the vertebral bodies and six patients had ankylosis 
of the facet joints. In comparison, lateral radiographs 
showed new bone formation in 26 (53%) patients at 
baseline (from C2/C3 to C7/T1 and from T12/L1 to 
L5/S1); 9 patients had ankylosis of the vertebral bodies. 
Thus, MRI was markedly less sensitive in the lumbar and 
cervical areas than radiography, while the specificity for 
any spur/ankylosis by MRI was 99.6%, with radiographs 
as reference standard. Erosions and new bone forma-
tion remained largely unchanged as assessed by MRI. In 
Figure 3 Mean values of CANDEN spine inflammation score and for vertebral body and posterior elements subscores, bars 
represent the SEM; as observed (n=49, 47, 42, 39). For comparison, change in SPARCC MRI spine index (23-DVU) is also 
shown. P values for difference between group at week 6 were calculated in post hoc secondary analyses by ANCOVA. Bar 
plots show changes from baseline to week 6 with P values for the difference between change values at week 6 calculated by 
Mann-Whitney U tests with continuity correction (per protocol); as observed (n=47). MRI scores were the average of the two 
readers. CANDEN,Canada-Denmark; DVU, discovertebral unit; SPARCC, Spondyloarthritis Research Consortium of Canada.
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comparison, two new bone spurs and ankylosis at three 
DVUs developed between baseline and week 48 as judged 
by radiographic scoring.
Inter-reader reliability and smallest detectable difference
CANDEN spine inflammation score had good to very 
good reliability for both status scores (inter-reader 
ICC of the 4 timepoints mean 0.82) and change scores 
(from baseline to the 3 follow-up timepoints mean 0.72), 
similar to that of the SPARCC MRI spine index (ICC 0.82 
for status score, 0.76 for change scores). Inter-reader 
reliability of SPARCC for reader pairs WM-SJP/WM-SK 
was 0.80/0.79 for status scores and 0.86/0.83 for change 
scores, which confirms that the two CANDEN readers of 
this study (SJP and SK) were well calibrated according to 
the SPARCC method. The FASSS had a very good relia-
bility (ICC mean 0.92 for status score and 0.71 for change 
score, respectively). Reliability for status score was good 
to very good for CANDEN spine erosion score (mean 
0.61) and CANDEN spine new bone formation score 
(mean 0.75), while reliability for change scores were 
poor (all <0.40). At week 24, SDC was 7 points for the 
CANDEN total spine inflammation score; in comparison 
SPARCC score had a SDC of 8 points; six patients had an 
improvement in inflammation ≥SDC using either scoring 
method. The FASSS had a SDC of 2 points; at week 24, 
12 patients had an increase above this threshold. Only 
limited changes in erosion score and new bone forma-
tion score were observed.
dIsCussIon
We have developed and preliminarily validated a new, 
comprehensive set of anatomy-based MRI outcome meas-
ures for spinal inflammation (CANDEN spine inflamma-
tion score) and structural changes (CANDEN spine new 
bone formation score, CANDEN spine erosion score) 
in patients with axSpA in a randomised controlled trial 
based on previously published CANDEN MRI definitions.
The inflammatory component, the CANDEN spine 
inflammation score, possessed face, content and 
construct validity as well as good sensitivity to change and 
discrimination. Inflammation in axSpA involves different 
tissues, such as the fibrocartilaginous joints between the 
vertebral bodies that include the ring apophysis where 
the annulus fibrosus inserts, the synovial facet joints and 
Table 4 Baseline distribution and responsiveness of Canada-Denmark spine inflammation and structural scores compared 
with SPARCC and BASDAI
Measurement instrument
Observed 
range Mean (SD)
Median 
(IQR)
GRI at 
week 6
SRM at 
week 6
SRM at 
week 24
SRM at 
week 48
Number of patients analysed 49 49 49 47 47 42 39
Canada-Denmark spine total 
inflammation score
(range 0–582)
0–54 8.8 (12) 4 (1–12) 1.88 0.46 0.57 0.55
  Vertebral body subscore
  (range 0–456)
0–48 8.2 (11) 4 (1–12) 1.99 0.47 0.57 0.55
   Anterior corner subscore 0–23 3.6 (5.0) 2 (1–5) 1.64 0.40 0.57 0.59
   Posterior corner subscore 0–12 1.4 (2.5) 0 (0–2) 2.56 0.33 0.46 0.45
   Non-corner subscore 0–12 1.2 (2.8) 0 (0–0) 0.35 0.30 0.34 0.27
   Lateral corner subscore 0–16 2.0 (3.2) 1 (0–3) 1.08 0.45 0.48 0.49
  Posterior elements subscore (range 
0–126)
0–10 0.6 (1.7) 0 (0–0) 0.84 0.18 0.37 0.35
Canada-Denmark spine erosion 
score (range 0–320)
0–7 0.7 (1.4) 0 (0–1) 0.20 0.00 0.21 0.19
Fat Spondyloarthritis Spine 
Score (range 0–456)
0–39 5.5 (8.8) 2 (0–7) 1.25 0.21 0.38 0.38
Canada-Denmark spine new bone 
formation score (range 0–460)
0–123 7.5 (20) 0 (0–3) 0.22 0.37 0.51 0.48
SPARCC MRI spine index (23-
DVU) (range 0–414)
0–52 9.8 (13) 4 (1–14) 1.67 0.48 0.57 0.55
mSASSS 0–61 7.2 (14) 2 (0–6) NA NA NA 0.35
BASDAI (range 0–10) 4.2–9.8 6.4 (1.3) 6.3 (5.4–7.2) 1.32 0.69 1.64 1.96
Median, range and IQR are for all 49 patients. Responsiveness was assessed by SRM and GRI for all patients who had an MRI scan 
performed at the follow-up timepoint. MRI scores were the average of the two readers. Lateral corner subscore is the sum of antero-lateral 
and postero-lateral lesion scores.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DVU, discovertebral unit; GRI, Guyatt’s Responsiveness Index; mSASSS, 
modified Stoke Ankylosing Spondylitis Spine Score; SPARCC, Spondyloarthritis Research Consortium of Canada; SRM, standardised 
response mean.
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costotransverse joints and the complex synovial costover-
tebral joints where most ribs articulate with facets on the 
margins of adjacent thoracic vertebral bodies and the 
intervertebral disc, as well as numerous entheseal sites, 
especially in the posterior elements. These different sites 
may respond differently to drugs with various modes of 
action. Thus, the detailed CANDEN system may allow 
an increased understanding of how different drugs may 
modify different aspects of the spinal disease.
In contrast to currently used MRI scoring methods of 
the spine such as the SPARCC system, which is based on 
assessment of the vertebral bodies on three consecutive 
slices at each discovertebral unit, and does not record 
whether inflammation is present as non-corner lesions, 
lateral lesions or anterior corner lesions, this anato-
my-based assessment system provides this information. 
The system measures inflammation in the entire spine, 
including different parts of the posterior elements of the 
spine, providing greater face and content validity. First, 
the posterior elements constitute a large volume of the 
vertebrae and have large surface areas with insertions 
of ligaments and tendons, and there is no reason why 
inflammation here should be less clinically relevant to 
the patients. Second, the specificity of inflammation of 
the costotransverse, costovertebral and facet joints may 
be greater for axSpA, compared with the corner and 
particularly the non-corner inflammatory lesions of the 
vertebral bodies, which may be seen in healthy controls 
and in patients with degenerative disc disease.17–19
The pattern and prevalence of inflammatory and struc-
tural changes at different anatomical locations in a popu-
lation of patients starting TNF inhibitor treatment was 
described, and found to be highest in the lower thoracic 
and lumbar spine. The frequency of posterior findings 
was lower than expected, as only six (12%) patients had 
inflammatory lesions of the posterior elements in this 
trial. Lesions in the posterior elements only gave a minor 
contribution to the total mean scores. Interestingly, all 
six patients with inflammatory lesions of the posterior 
elements were HLA-B27 positive and fulfilled the radio-
graphical criteria for ankylosing spondylitis (AS), and 
4 (67%) were clinical responders at week 24. This may 
suggest that posterior elements are rarely involved in 
nr-axSpA, but this needs further investigation.
Other studies have reported higher prevalences of 
involvement of the posterior elements. Bochkova et al 
found inflammatory lesions of the posterior elements in 
22 (76%) of 29 patients that all fulfilled the radiographic 
criteria for AS and almost all (28 (97%) of 29) were 
HLA-B27 positive.20 They performed additional axial 
images at painful regions of the spine in case of normal 
sagittal images, which may increase sensitivity. Maksy-
mowych et al found inflammatory lesions of the posterior 
elements in 28 (88%) of 32 patients with AS.14 Althoff et 
al found inflammatory lesions of the posterior elements 
more often in the AS group (10 (26%) of 39) than in the 
non-radiographic axSpA group (3 (8%) of 36).21 Larbi 
et al found inflammatory lesions in 23 of 112 (21%) of 
recently diagnosed HLA-B27-positive patients with SpA.22 
In comparison, in our study 36 (73%) were HLA-B27 
positive and 28 (57%) fulfilled the radiographical criteria 
for AS. Thus, the lower prevalence of posterior inflamma-
tory lesions in our study may be due to a different case 
mix of patients compared with the other studies.
Most vertebral non-corner inflammatory lesions that 
were present at baseline had disappeared after 24 weeks 
(56%), and the number of new similar lesions that devel-
oped during the trial was minimal. Still, other inflamma-
tory lesions such as anterior and posterior corner lesions 
disappeared even more frequently during treatment. 
Non-corner lesions are often seen as a part of endplate 
lesions similar to a Modic type I lesion, and disc degen-
eration rather than spondyloarthritis will be a probable 
cause of some of these lesions.
Rennie et al have reported that lesions in 20% of 
inflamed vertebral bodies were only visible on ‘lateral’ 
sagittal MRI slices.23 A comparable result was reached in 
our study, where 14% of inflamed vertebral bodies were 
only visualised on the lateral slices. The spatial distri-
bution of syndesmophytes along the vertebral rim has 
been demonstrated by CT to involve most of the circum-
ference, preferentially the postero-lateral rim,23 and 
including as much of the rim as possible in the scoring 
should increase the sensitivity of the instrument. This 
underlines the need for assessing central sagittal slices, 
and lateral sagittal slices, if a comprehensive score for all 
inflammatory lesions in the vertebral bodies is needed. 
The SPARCC spine method does assess lateral inflamma-
tion in the vertebral body, as the three consecutive slices 
approach can be applied to lesions in the lateral slices in 
the same manner as for central slices.
At baseline, only six patients (12%) had inflammatory 
lesions in the posterior elements, and all these had also 
lesions in the vertebral bodies. The GRI for the total 
CANDEN spine inflammation score and for the verte-
bral body subscore were almost identical. The addition 
of posterior elements data to the vertebral body subscore 
did not improve responsiveness. The low frequency of 
posterior lesions in this study likely accounts for the lack 
of impact of including these elements. The responsive-
ness measures SRM and GRI assume that change scores 
are normally distributed; many patients in this study had 
little spinal involvement and therefore no change over 
time, and these responsiveness measures would likely 
have been higher if the case mix had consisted of more 
patients with substantial spinal involvement. Impor-
tantly, the responsiveness of the CANDEN spine inflam-
mation score was similar to that of the SPARCC MRI 
spine index. It is important to note that a method that 
focuses on assessing presence/absence and size of indi-
vidual lesions, such as CANDEN, may perform differently 
than a method that has been designed to assess the total 
amount of inflammation, independent of location, such 
as SPARCC, in groups of patients with many spinal lesions 
as compared to those with few. Consequently, comparison 
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of responsiveness and discrimination will be required in 
larger cohorts with a broader range of spinal lesions.
In this study, the fat metaplasia score (FASSS) tended 
to increase over time, and week 24 change in FASSS 
correlated with the disappearance of inflammatory 
lesions. This temporal association, and the fact that 84% 
of new fat lesions occurred in areas in which inflamma-
tion had been present at baseline, further validates the 
FASSS score as a measure of structural changes caused by 
inflammation. Bone spurs and ankylosis of the vertebral 
bodies were observed more frequently by radiography 
than MRI, but MRI allowed an assessment of the thoracic 
spine and facet joints that are difficult to delineate on 
lateral radiographs and that are not included in the 
mSASSS score for radiographic changes. Further studies 
with longer follow-up are needed to clarify the clinical 
importance of these structural measures as well as finding 
possible ways to improve their reliable detection by MRI.
It is important to note that the CANDEN scores are 
not intended to be used to diagnose axSpA, but rather 
to allow detailed monitoring of changes over time in 
patients who have already been diagnosed with axSpA. 
The value of the CANDEN system is that it allows more 
detailed analyses of the link between inflammation and 
structural changes and their development over time 
and at the same time may provide a patient-level score 
for spinal inflammation. Ten patients did not complete 
the trial,15 but since their baseline characteristics were 
similar to the other patients (data not shown), the results 
presented here were likely not impacted.
In conclusion, the present study documents the 
construct validity, responsiveness, discriminatory ability 
and reliability of the CANDEN spine inflammation score. 
The method is a promising outcome measure in patients 
with axSpA, as it both allows assessment of the total spinal 
inflammation, and also separate analyses of various artic-
ular, entheseal and discovertebral components of the 
disease. Through comprehensive assessment of all parts 
of the spine, it has inherently good face and content 
validity. The structural CANDEN spine scores showed 
good cross-sectional reliability, but further studies with 
longer follow-up are needed to clarify the validity and 
utility in clinical trials and longitudinal cohorts.
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